Gilead Sciences (GILD)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-30
$170.68+3.06%
Close 2026-10-30 · 1-day change
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-30
Research Workspace
Put GILD beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Product sales excluding Veklury reach $29.4B to $29.8B: Direct metric needs a verified mapping.
View ThesisRevenue is growing steadily — about 7% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 18%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskGilead’s sales growth and HIV prevention franchise are the core case, supported by robust cash-backed earnings. Revenue growth slowed from 10% in Q2 to 7% in Q3, despite another earnings beat. Gilead trades at 7× sales versus a 9× peer median, and expectations look modest versus our view. The premium over its own historical multiple of 6× also needs support. A key risk is the 2028 Biktarvy price cut, which could pressure sales growth. The product-sales pillar is under pressure because its metric mapping needs verification. Peer multiples imply a price about 14% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-30. GILD is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 28 analysts currently covering GILD (as of Oct 2026).
Based on 11 Wall Street analysts offering 12-month price targets for GILD in the last 4 months.
Continue this research
Compare GILD with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| GILD Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 4 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put GILD next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase product sales excluding Veklury
Raised 2026 sales outlook supports ex-Veklury growth; 2028 Biktarvy price cuts are a future headwind.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $170.68
The last 12 months of price, then the range of analyst 12-month targets from today’s $170.68.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Expand oncology and inflammation through pipeline and acquisitions
Named oncology trial collaboration broadens development activity but remains early.
Advances: Expand oncology and inflammation through pipeline and acquisitions
Positive mid-stage oral bowel-disease trial supports pipeline expansion beyond core franchises.
Advances: Advance lenacapavir for HIV prevention
India's eased approval pathway supports potential access for long-acting HIV prevention.
Advances: Advance lenacapavir for HIV prevention
Licensing deal expands lenacapavir access and supports global HIV prevention reach.
Advances: Expand oncology and inflammation through pipeline and acquisitions
Assembly Bio exercising its Gilead profit option advances the partnership's development economics.
Multiple recent FDA approvals demonstrate execution and expand commercial opportunity.
Advances: Advance lenacapavir for HIV prevention
FDA approval of lenacapavir combination expands HIV treatment options and validates the platform.
